Clinical reviews

← vista completa

Published on January 7, 2015 | http://doi.org/10.5867/medwave.2015.01.6062

Polyunsaturated fatty acids for multiple sclerosis treatment

Ácidos grasos poliinsaturados en el tratamiento de la esclerosis múltiple

Monserrat Kong-González , Jesús Giovanni Pérez-Cortéz, Carlos Hernández-Girón, Nayeli Macías-Morales, Mario Flores-Aldana

Abstract

INTRODUCTION Fatty acids have an important role in structure and function of the nervous system. Recently, epidemiologic studies on neurodegenerative disorders have evaluated the usefulness of polyunsaturated fatty acids on multiple sclerosis.

OBJECTIVE To examine recent studies, clinical trials, and reviews on the therapeutic effect of polyunsaturated fatty acids in multiple sclerosis.

METHODS We conducted a search in MEDLINE/PubMed and Cochrane Library with the terms "fatty acids", "omega-3" and "omega-6" in combination with "multiple sclerosis". Articles were selected according to their relevance on the topic.

RESULTS Epidemiologic studies have shown benefits of dietary supplementation with polyunsaturated fatty acids -especially omega-3- in relation to inflammatory, autoimmune and neurodegenerative disorders. In contrast, the studies do not show a beneficial effect of polyunsaturated fatty acids in multiple sclerosis. However, there are limitations related to design and sample issues in these studies

CONCLUSIONS There is some evidence of a protective effect of polyunsaturated fatty acids on the risk of multiple sclerosis. Despite this, to date controlled trials have not produced definite results on the benefits of supplementation with polyunsaturated fatty acids in patients with multiple sclerosis. Any potential benefit will have to be confirmed in the long term.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Monserrat Kong-González

Escuela de Nutrición, Campus Universitario Siglo XXI, Toluca, Estado de México, México

chernand@insp.mx

Av

Jesús Giovanni Pérez-Cortéz

Campus de la Salud, Universidad Latinoamericana, Cuernavaca, Morelos, México

Carlos Hernández-Girón

Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México

Nayeli Macías-Morales

Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México

Mario Flores-Aldana

Centro de Investigación en Nutrición y Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México

Figures

Article has no figures.

Forum

No messages

History

Citation Kong-González M, Pérez-Cortéz JG, Hernández-Girón C, Macías-Morales N, Flores-Aldana M. Polyunsaturated fatty acids for multiple sclerosis treatment. Medwave 2015;15(01):e6062 doi: 10.5867/medwave.2015.01.6062

Submission date 07/11/2014

Acceptance date 23/12/2014

Publication date 07/01/2015

Index

Metrics

Not available at the moment.

Notes

Keywords

múltiple sclerosis, polyunsaturated fatty acids, PUFA, narrative review

Origin and peer review

con revisión por un revisor externo, a doble ciego

References

  1. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008 Mar;7(3):268-77. | CrossRef | PubMed
  2. Harbige LS. Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc. 1998 Nov;57(4):555-62. | PubMed
  3. Yadav V, Shinto L, Bourdette D. Complementary and alternative medicine for the treatment of multiple sclerosis. Expert Rev Clin Immunol. 2010 May;6(3):381-95. | CrossRef | PubMed
  4. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005 Sep;252(Suppl 3):iii3-iii9. | PubMed
  5. Casanova-Estruch B, Coret-Ferrer F, Landete L, Burgal M. [Axonal involvement in multiple sclerosis. Current concepts]. Rev Neurol. 2000 May 16-31;30(10):972-6. | PubMed
  6. Mouzaki A, Tselios T, Papathanassopoulos P, Matsoukas I, Chatzantoni K. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr Neurovasc Res. 2004 Oct;1(4):325-40. | PubMed
  7. Alemany-Rodríguez MJ, Aladro Y, Amela-Peris R, Pérez-Viéitez MC, Reyes-Yáñez MP, Déniz-Naranjo MC, et al. [Autoimmune diseases and multiple sclerosis]. Rev Neurol. 2005 May 16-31;40(10):594-7. | PubMed
  8. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989 Feb;112 ( Pt 1):133-46. | CrossRef | PubMed
  9. Hawker K, Frohman E. Multiple sclerosis. Prim Care. 2004 Mar;31(1):201-26. | PubMed
  10. Velázquez-Quintana M, Macías-Islas MA, Rivera-Olmos V, Lozano-Zárate J. [Multiple sclerosis in Mexico: a multicentre study]. Rev Neurol. 2003 Jun;36(11):1019-22. | PubMed
  11. Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology. 1979 Sep;29(9 Pt 1):1228-35. | PubMed
  12. Ruiz García D, Solar Salaberry LA. Esclerosis múltiple. Revisión bibliográfica. Rev Cubana Med Gen Integr. 2006;22(2):1-11. | Link
  13. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med. 2006 Jan;73(1):91-102. | CrossRef | PubMed
  14. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993 Feb;20(1):17-29. | PubMed
  15. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008 Feb;194(1-2):7-17. | CrossRef | PubMed
  16. Harbige LS, Sharief MK. Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis. Br J Nutr. 2007 Oct;98 Suppl 1:S46-53. | CrossRef | PubMed
  17. Galli C, Marangoni F. Recent advances in the biology of n-6 fatty acids. Nutrition. 1997 Nov-Dec;13(11-12):978-85. | PubMed
  18. deDeckere EAM, Korver O, Verschuren PM, Katan MB. Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin. Eur J Clin Nutr 1998;52(10):749-53. | PubMed
  19. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 2001;21(4):481-7. | CrossRef | PubMed
  20. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005 Oct;115(10):2774-83. | CrossRef | PubMed
  21. Erkkilä A, de Mello VD, Risérus U, Laaksonen DE. Dietary fatty acids and cardiovascular disease: an epidemiological approach. Prog Lipid Res. 2008 May;47(3):172-87. | CrossRef | PubMed
  22. Carlson SE. Docosahexaenoic acid and arachidonic acid in infant development. Semin Neonatol. 2001 Oct;6(5):437-49. | PubMed
  23. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000 Sep;102(3):143-9. | CrossRef | PubMed
  24. Swank RL, Lerstad O, Strøm A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med. 1952 May 8;246(19):722-8. | PubMed
  25. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007 May;101(3):577-99. Epub 2007 Jan 25. | CrossRef | PubMed
  26. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S. | PubMed | Link
  27. Liuzzi GM, Latronico T, Rossano R, Viggiani S, Fasano A, Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells--implications for complementary multiple sclerosis treatment. Neurochem Res. 2007 Dec;32(12):2184-93. | PubMed
  28. Liuzzi GM, Latronico T, Fasano A, Carlone G, Riccio P. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler. 2004 Jun;10(3):290-7. | PubMed
  29. Meade CJ, Mertin J, Sheena J, Hunt R. Reduction by linoleic acid of the severity of experimental allergic encephalomyelitis in the guinea pig. J Neurol Sci. 1978 Feb;35(2-3):291-308. | PubMed
  30. Hughes D, Keith AB, Mertin J, Caspary EA. Linoleic acid therapy in severe experimental allergic encephalomyelitis in the guinea-pig: suppression by continuous treatment. Clin Exp Immunol. 1980 Jun;40(3):523-31. | PubMed
  31. Harbige LS, Layward L, Morris-Downes MM, Dumonde DC, Amor S. The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. Clin Exp Immunol. 2000 Dec;122(3):445-52. | CrossRef | PubMed
  32. Harbige LS, Morris M, Amor S. Modulatory action of essential fatty acids on experimental allergic encephalomyelitis (EAE). J Neuroimmunol. 1994;52(2):113 | CrossRef
  33. Kong W, Yen JH, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011 Jul;25(5):872-82. | CrossRef | PubMed
  34. Torkildsen Ø, Brunborg LA, Thorsen F, Mørk SJ, Stangel M, Myhr KM, et al. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol. 2009 Jan;215(1):160-6. | CrossRef | PubMed
  35. Unoda K, Doi Y, Nakajima H, Yamane K, Hosokawa T, Ishida S, et al. Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013 Mar 15;256(1-2):7-12. | CrossRef | PubMed
  36. Shinto L, Marracci G, Baldauf-Wagner S, Strehlow A, Yadav V, Stuber L, et al. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar;80(2-3):131-6. | CrossRef | PubMed
  37. Ikemoto A, Ohishi M, Sato Y, Hata N, Misawa Y, Fujii Y, et al. Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level of n-6 fatty acids as another critical factor. J Lipid Res. 2001 Oct;42(10):1655-63. | PubMed
  38. Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-Kwen P, Gallagher E, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005 Nov;73(5):397-404. | PubMed
  39. Swank RL, Grimsgaard A. Multiple sclerosis: the lipid relationship. Am J Clin Nutr. 1988 Dec;48(6):1387-93. | PubMed | Link
  40. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet. 1990 Jul 7;336(8706):37-9. | CrossRef | PubMed
  41. Swank RL. Multiple sclerosis: twenty years on low fat diet. Arch Neurol. 1970 Nov;23(5):460-74. | CrossRef | PubMed
  42. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch Neurol. 1974 Oct;31(4):267-72. | CrossRef | PubMed
  43. Bates D. Lipids and multiple sclerosis. Biochemical Society Transactions. 625th meeting, London 1988;17:289-91.
  44. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):18-22. | PubMed | Link
  45. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol. 1995 Oct 1;142(7):733-7. | PubMed
  46. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol. 1998 Oct;27(5):845-52. | PubMed
  47. Zhang SM, Hernán MA, Olek MJ, Spiegelman D, Willett WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology. 2001 Jul 10;57(1):75-80. | PubMed
  48. Kelley DS. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition. 2001 Jul-Aug;17(7-8):669-73. | CrossRef | PubMed
  49. Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, Albers R, et al. Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am J Clin Nutr. 2003 May;77(5):1287-95. | PubMed | Link
  50. Ebers P. Multiple Sclerosis, Pennsylvania: FA. Davis Company, 1998: 404–420
  51. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil. 2003 Dec;84(12):1823-30. | PubMed
  52. Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet. 2001 Oct;14(5):349-57. | CrossRef | PubMed
  53. Williams CM, Lines CM, McKay EC. Iron and zinc status in multiple sclerosis patients with pressure sores. Eur J Clin Nutr. 1988 Apr;42(4):321-8. | PubMed
  54. Thomas FJ, Wiles CM. Dysphagia and nutritional status in multiple sclerosis. J Neurol. 1999 Aug;246(8):677-82. | PubMed